Jul 6, 2023 by James HalleyWhy Shares of Caribou Biosciences Are Skyrocketing TodayThe company's shares spiked after Pfizer bought $25 million of Caribou stock.
Jul 5, 2023 by James HalleyWhy Shares of Canopy Growth Are Dropping WednesdayAn analyst downgraded the stock to a $0 price target.
Jul 5, 2023 by James HalleyWhy Shares of Amneal Pharmaceuticals Are Plunging WednesdayThe company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.
Jul 5, 2023 by James HalleyWhy Shares of Cassava Sciences Are Dropping WednesdayThe company announced phase 3 trial results for its lead Alzheimer's therapy.
Jul 3, 2023 by James HalleyWhy Shares of Ventyx Biosciences Rose MondayThe company has several promising autoimmune therapies.
Jul 3, 2023 by James HalleyWhy Shares of Labcorp Dropped MondayThe company completed the spinoff of contract research organization Fortrea Holdings.
Jul 3, 2023 by James HalleyWhy Shares of Canopy Growth Jumped MondayThe cannabis company announced financial restructuring to help its bottom line.
Jul 3, 2023 by James HalleyMerck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still BuysBoth companies are facing significant patent cliffs, but they've been preparing for this moment.
Jul 1, 2023 by James Halley1 Green Flag and 1 Red Flag for PfizerPfizer's long-term potential shows promise, but concerns exist.
Jun 30, 2023 by James HalleyWhy Shares of Belite Bio Soared This WeekThe clinical-stage biotech company bounced back from a 52-week low late last week.
Jun 30, 2023 by James HalleyWhy Shares of AC Immune Jumped This WeekThe FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.
Jun 30, 2023 by James HalleyWhy Shares of Alvotech Are Jumping FridayThe biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback.
Jun 30, 2023 by James HalleyWhy Shares of CymaBay Therapeutics Are Soaring FridayA competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.
Jun 29, 2023 by James HalleyWhy Shares of Black Diamond Therapeutics Skyrocketed This WeekThe company announced positive early-trial news for non-small cell lung cancer.
Jun 29, 2023 by James HalleyWhy Shares of Opko Health Jumped on ThursdayThe FDA approved a growth therapy the company was collaborating on with Pfizer.
Jun 29, 2023 by James HalleyWhy Shares of CorMedix Are Slumping ThursdayThe company announced a stock sale and the sale of prefunded warrants.
Jun 29, 2023 by James HalleyWhy Shares of BioXcel Therapeutics Are Plunging ThursdayQuestions regarding the safety of an Alzheimer's disease agitation therapy were raised when the company announced phase 3 trial results.
Jun 29, 2023 by James Halley2 Unstoppable Growth Stocks to Buy in 2023 and BeyondBoth companies have therapies that should help grow revenue and earnings for years.
Jun 28, 2023 by James HalleyWhy Shares of Axsome Therapeutics Fell WednesdayThe biopharmaceutical company announced a $225 million stock sale.
Jun 28, 2023 by James HalleyWhy Shares of Roivant Sciences Rose WednesdayThe pharmaceutical company released fourth-quarter earnings.
